Physician profile
Daniel E Lynch
NPI 1922027705
$2,785.01
in general payments reported to CMS, 2019-2025
31 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $187 · 2021: $645 · 2022: $675 · 2023: $219 · 2024: $213 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.49 | 2019-2024 | Relistor |
| Medtronic, INC. | $333.10 | 2021-2022 | |
| Si-Bone, INC. | $311.88 | 2021-2023 | |
| Medtronic USA, INC. | $223.25 | 2019 | |
| Stryker Corporation | $177.43 | 2024-2025 | Pangea, Spinejack |
| Pfizer INC. | $168.37 | 2019-2021 | |
| Grt US Holding, INC. | $153.62 | 2021-2022 | |
| Mdd US Operations, LLC | $133.87 | 2019 | |
| Abbvie INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $92.49 | 2019 | |
| Acadia Pharmaceuticals INC | $85.15 | 2023 | Nuplazid |
| Arbor Pharmaceuticals, INC. | $67.43 | 2020-2021 | |
| Boston Scientific Corporation | $63.43 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Pacira Therapeutics, INC. | $57.22 | 2019 | |
| Scilex Pharmaceuticals INC. | $54.56 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $53.76 | 2022 | |
| Averitas Pharma INC. | $42.89 | 2023-2024 | Qutenza |
| Redhill Biopharma INC. | $40.37 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $36.86 | 2023 | Xtampza, Belbuca |
| Merck Sharp & Dohme LLC | $33.66 | 2022 | |
| Amgen INC. | $29.24 | 2021 | |
| Bioventus LLC | $21.44 | 2019 | |
| Allergan, INC. | $17.89 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $17.58 | 2024 | |
| Eisai INC. | $16.04 | 2021 | |
| Glaxosmithkline, LLC. | $14.57 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.49 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $14.38 | 2023 | Quviviq |
| Stimwave Technologies Incorporated | $12.53 | 2019 | |
| Novo Nordisk INC | $12.14 | 2021 | |
| Zimmer Biomet Holdings, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.